Weifa

Weifa is a Norwegian pharmaceutical company headquartered in Oslo with production facilities in Kragerø.

Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.

History
Weifa was founded by pharmacist Olaf Weider in 1940.

Therapeutic areas
Weifa focuses on three therapeutic areas:
 * 1) Pain management
 * 2) Diabetes management
 * 3) Food supplements

Products

 * bra!: Evening primrose oil.
 * Bronkyl: Expectorant effervescent tablet.
 * Dexyl: Nasal spray.
 * Fanalgin: Pain reliever and fever reducer with an addition of caffeine.
 * Ferromax: Iron supplement.
 * Fluormax: Fluorine supplements.
 * Ibux: A brand name for ibuprofen.
 * Ibux Gel: A gel version of Ibux.
 * Nazamér: Salt water spray.
 * Nazaren: Salt water nasal spray.
 * Paracet: A brand name for paracetamol.
 * Paracetduo: Similar to Paracet with the addition of caffeine for increased pain relief.
 * Proxan: Brand name for naproxen.
 * Pyrivir: Relieves symptoms of cold sores.
 * Samin: Symptom relief in patients with Osteoarthritis.
 * Tigerbalsam: Heat rub.
 * Tussin: Cough medicine.
 * Weifa-C Nypeekstrakt: Vitamin C from rose hip extract.
 * Weifa C-vitamin brusetabletter: Vitamin C effervescent tablets.
 * Weifa Kalsium: Calcium supplements.

Active ingredients

 * Codeine: Used in pain relievers and cough medicine.
 * Metformin: Used in first-line treatment of diabetes mellitus type 2.
 * Pholcodine: Used in cough medicine.

Development
With a total of over 99 employees, Weifa is today generating an annual turnover of approximately €40 million (35% of the turnover is achieved internationally). Weifa bases its development on 3 criteria:
 * 1) International expansion
 * 2) Expertise in pharmaceuticals and fine chemicals
 * 3) Partnership agreements

Norway
Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.

Export
Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.